Manuel Pedregal
Harvard University
4 Papers
3 Citations
Manuel Pedregal is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy
Christian D. Fankhauser,Ben Tran,Manuel Pedregal,Jose Manuel Ruiz-Morales,Egon Gonzalez-Billalabeitia,Anna Patrikidou,Eitan Amir,Christoph Seidel,Carsten Bokemeyer,Thomas Hermanns,Alexey Rumyantsev,Alexey Tryakin,Margarida Brito,Aude Flechon,Edmon M. Kwan,Tina Cheng,Daniel Castellano,Xavier Garcia del Muro,Anis A. Hamid,Margaret Ottaviano,Giovanella Palmieri,Robert Kitson,Alison Reid,Daniel Y.C. Heng,Philippe L. Bedard,Christopher Sweeney,Jean M. Connors +26 more
TL;DR: It is found that venous thromboembolic events (VTEs) occur rarely after chemotherapy and the risk of VTE in men undergoing chemotherapy for metastatic germ cell tumours can be decreased by thromboprophylaxis with a reasonable risk-benefit profile and by avoidance of venous access devices.
20
Linking pBRD4 and PP2A inhibition in triple negative breast cancer.
Manuel Pedregal,Ion Cristóbal,Francisco J. Lobo,Yann Izarzugaza,Cristina Carames Sanchez,Victor Moreno,Tatiana Hernandez,Jaime Rubio,Sandra Zazo,Blanca Torrejón,Federico Rojo,Jesús García-Foncillas +11 more
TL;DR: It is reported here that BRD4 hyperphosphorylation is a common event that defines a subgroup of TNBC patients with very poor outcome that is found associated with higher tumor grade and with the sub group of cases who relapsed.
2
Immunotherapy for Peritoneal Metastases from Gastric Cancer: Rationale, Current Practice and Ongoing Trials.
TL;DR: In this article, the authors address the current state-of-the-art immunotherapy treatment of peritoneal dissemination and propose new strategies for intraperitoneal immunotherapy for different ongoing clinical trials.